48例重度慢性阻塞性肺疾病患者的治疗效果观察及分析

Analysis on the efficacy of 48 patients with severe chronic obstructive pulmonary disease

目的探讨小剂量氨茶碱联合布地奈德在治疗重度COPD患者的临床效果。方法人选2013年1-12月我院收治的48例重度COPD患者，根据治疗方案不同分为观察组与对照组，各24例。观察组给予小剂量氨茶碱联合布地奈德，对照组仅给予布地奈德。观察两组患者治疗有效率及运动耐量的变化。结果观察组治疗有效率为91．67％，高于对照组的62．50％，差异有统计学意义（P〈0．05）；运动耐量检测采用6分钟步行距离（6MWD），治疗前两组6MWD、MRC比较，差异无统计学意义（P〉0．05），治疗后，观察组6MWD为（345．97±20．35）m，明显高于对照组的（304．99±18．32）m，差异有统计学意义（P〈0．05）。治疗后，观察组MRC得分（3．56±0．58），明显高于对照组（4．11±0．65），差异有统计学意义（P〈0．05）。结论小剂量氨茶碱联合布地奈德在治疗重度COPD患者中具有较好的临床疗效，并能够有效提高患者运动耐量，提升生活质量，值得临床推广。

Objective To explore the clinical effects of small dose aminophylline combined with budesonide in the treatment of severe chronic obstrtactive pulmonary disease （COPD） patients. Methods Forty-eight cases of severe COPD patients were treated from January 2013 to December 2013 in our hospital,according to the different treatment schemes were divided into observation group and control group, 24 cases in each group. The observation group was given small dose aminophylline and budesonide, while the control group was treated with budesonide. To observe the change of the effective rate and exercise tolerance in patients of the two groups. Results The effective rate of treatment group was 91.67% ,higher than 62.50%of the control group was, there was significant difference （P 〈0.05）. Exercise tolerance test by 6 minutes walk disttmce （6MWD）, two groups of 6MWD had no significant difference （P 〉 0.05） before treatment and after treatment, 6MWD of the observation group was （345.97±20.35） m after treatment,significantlly higher than （304.99±18.32） m of the control group, there was significant difference （ P 〈0.05）. After treatment, MRC score in the observation group was （3.56±0.58） ,was significantly higher than that in control group （4.11±0.65） ,there was significant difference （ P〈0.05）. Conclusions Small dose aminophylline budesonide has a good clinical efficacy in the treatment of patients with severe COPD, and can effectively improve the exercise tolerance in patients, improve the quality of life,and is worthy of clinical application.